Table 1.
Clinical applications of mesenchymal stem cells in feline disease
| Disease | Study type | MSC source | Interventions | Outcome | Reference |
|---|---|---|---|---|---|
| Gingivostomatitis | Open-label, baseline-controlled clinical trial | Autologous adipose-derived | Two doses IV aMSCs 30 days apart (7 cats) | Complete remission (3 cats), substantial improvement (2 cats), no response (2 cats) | Arzi et al 18 |
| Gingivostomatitis | Open-label, baseline-controlled clinical trial | Allogeneic adipose-derived | Two doses IV aMSCs 30 days apart (7 cats) | Complete remission (2 cats), substantial improvement (2 cats), no response (3 cats) | Arzi et al 8 |
| Acute experimental asthma | Randomized, placebo-controlled study | Allogeneic adipose-derived | Five doses IV aMSCs (4 cats), with 14, 14, 14, 70 and 30 days between each respective dose, or placebo (2 cats) | Decrease in airway eosinophilia, diminished airway hyper-responsiveness, decreased airway remodeling | Trzil et al 31 |
| Chronic experimental asthma | Randomized, placebo-controlled study | Allogeneic adipose-derived | Six doses IV aMSCs (5 cats) 14 days apart or placebo (4 cats) | Decreased airway remodeling | Trzil et al 30 |
| Chronic enteropathy | Owner-blinded, randomized, placebo-controlled clinical trial | Allogeneic adipose-derived | Two doses IV aMSCs 14 days apart (7 cats) or placebo (4 cats) | Improved clinical signs in 5/7 aMSC-treated cats and 0/4 placebo cats | Webb and Webb 29 |
| CKD | Open-label, baseline-controlled clinical trial | Autologous adipose-derived or bone marrow-derived | Single unilateral intrarenal injection of aMSCs (3 cats) or bMSCs (3 cats) | Mild decrease in serum creatinine and increase in GFR in 2 cats that received aMSCs | Quimby et al 24 |
| CKD | Three open-label, baseline-controlled, pilot clinical trials | Allogeneic adipose-derived | Three doses IV aMSCs 14 days apart (16 cats) | Mild decrease in serum creatinine in 7/15 cats (1 cat excluded due to medication non-compliance) and increase in GFR in 4/16 cats. Side effects included vomiting and increased respiratory rate | Quimby et al 25 |
| CKD | Randomized, placebo-controlled clinical trial | Allogeneic adipose-derived | Three doses IV aMSCs (4 cats) 14 days apart or placebo (3 cats) | No significant improvement in creatinine or GFR | Quimby et al 26 |
| Ischemic AKI | Randomized, placebo-controlled study | Allogeneic adipose-derived or bone marrow-derived | Single dose IV aMSCs (5 cats), bMSCs (5 cats) or fibroblasts (5 cats) 1 h after unilateral ischemia | No difference in percentage of cats with AKI | Rosselli et al 27 |
| CKD | Open-label, baseline-controlled clinical trial | Allogeneic amnion-derived | Two doses IV amnion-derived MSCs 21 days apart (9 cats) | Mild decrease in serum creatinine | Vidane et al 28 |
IV = intravenous; MSC = mesenchymal stem cell; aMSCs = adipose-derived MSCs; bMSCs = bone marrow-derived MSCs; GFR = glomerular filtration rate; AKI = acute kidney injury; CKD = chronic kidney disease